BackBetter Therapeutics Overview

Better Therapeutics Operating Income

Track Better Therapeutics's operating income ($-30M) with charts, peers, and YoY trends.

Get informed when a big investor buys or sells

+ Follow

Quarterly Operating Income

$-5341000.00
↓ 51.43% YoY

As of Sep 30, 2023

Annual Operating Income (TTM)

$-29613000.00
↓ 29.57% YoY

Trailing 12 months ending Sep 30, 2023

Average Operating Income (Comparison Companies)

Operating Income History

Operating Income Comparison

Annual Operating Income Growth Rate (%)

Annual Operating Income Growth (Absolute)

Jump to metric
Total RevenueCost of RevenueGross ProfitResearch & DevelopmentSelling, General & AdminOperating IncomeOther Income Expense NetEBITIncome TaxNet IncomeProfit Margin

Better Therapeutics (BTTX) FAQ

Better Therapeutics posts a operating income of $-30M as of September 2023. That compares with $-42M in the prior-year period — up 29.6% year over year. Comparing that reading with peers and prior periods is usually more useful than looking at the number in isolation.

In the prior comparable period, Better Therapeutics's operating income was $-42M. The latest reading is $-30M — a 29.6% year-over-year increase (period ending September 2023). Use the history and growth charts on this page for a longer lookback.

Operating Income is one piece of Better Therapeutics's financial statement story. At $-30M, it should be interpreted next to related metrics — for example revenue with costs, assets with liabilities, or income with margins. Stockcircle links those related pages so you can move from this number to the surrounding context quickly.

Context for BTTX's operating income usually means three checks: (1) trend versus prior periods, (2) level versus peers, and (3) consistency with growth and profitability. This page covers the first two; Better Therapeutics's other metric pages and overview cover the third.